A detailed history of Northern Trust Corp transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,107,169 shares of XERS stock, worth $3.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,107,169
Previous 1,159,555 4.52%
Holding current value
$3.13 Million
Previous $2.56 Million 2.77%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.7 - $2.45 $89,056 - $128,345
-52,386 Reduced 4.52%
1,107,169 $2.49 Million
Q1 2024

May 14, 2024

SELL
$2.04 - $3.22 $11,848 - $18,701
-5,808 Reduced 0.5%
1,159,555 $2.56 Million
Q4 2023

Feb 13, 2024

BUY
$1.47 - $2.36 $29,614 - $47,544
20,146 Added 1.76%
1,165,363 $2.74 Million
Q3 2023

Nov 13, 2023

SELL
$1.8 - $2.69 $15,418 - $23,042
-8,566 Reduced 0.74%
1,145,217 $2.13 Million
Q2 2023

Aug 11, 2023

BUY
$1.82 - $2.98 $80,454 - $131,733
44,206 Added 3.98%
1,153,783 $3.02 Million
Q1 2023

May 15, 2023

BUY
$1.03 - $1.63 $13,601 - $21,524
13,205 Added 1.2%
1,109,577 $1.81 Million
Q4 2022

Feb 13, 2023

BUY
$1.14 - $1.65 $1,993 - $2,885
1,749 Added 0.16%
1,096,372 $1.46 Million
Q3 2022

Nov 14, 2022

SELL
$1.37 - $1.93 $14,126 - $19,900
-10,311 Reduced 0.93%
1,094,623 $1.71 Million
Q2 2022

Aug 12, 2022

BUY
$1.48 - $2.64 $1.33 Million - $2.37 Million
898,486 Added 435.21%
1,104,934 $1.7 Million
Q1 2022

May 13, 2022

BUY
$2.0 - $2.87 $32,852 - $47,142
16,426 Added 8.64%
206,448 $529,000
Q4 2021

Feb 08, 2022

BUY
$1.8 - $2.93 $342,039 - $556,764
190,022 New
190,022 $557,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $385M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.